October 14, 2009

HELIX BIOPHARMA’S L-DOS47 TO BE HIGHLIGHTED AT PHARMACEUTICAL INDUSTRY CONFERENCE (PDF)

(AURORA, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: “HXBPF”) today announced that a presentation on L-DOS47 formulation and analytical method development will be made at the “Formulation
Strategies for Protein Therapeutics” conference to be held on October 13 to 15, 2009, in Raleigh, North Carolina. The conference is sponsored by IBC Life Sciences.